Latest Content

Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

May 15th 2025, 12:00pm

By Virginia Kaklamani, MD, DSc

Video

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

CX-2051 Proves Safe and Effective in Advanced Colon Cancer

May 14th 2025, 9:00pm

By Ryan Scott

Article

CX-2051 treatment demonstrated responses in patients with advanced, late-line colorectal cancer, according to interim data from the CTMX-2051-101 study.

Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs

May 14th 2025, 8:00pm

By Dr. Pietro Scilipoti

Video

Researchers followed patients for years and found that the risk of dying from prostate cancer depended on how aggressive the cancer was at diagnosis.

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

May 14th 2025, 6:36pm

By Ryan Scott

Article

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.

Survivors of Breast Cancer May Still Struggle with Fear of Recurrence

May 14th 2025, 6:00pm

By Bonnie Annis

Article

Even after many cancer-free years, the fear of recurrence still lingers, and many long-term survivors struggle to keep those thoughts at bay.

FDA Approves Welireg for Pheochromocytoma and Paraganglioma

May 14th 2025, 5:02pm

By Spencer Feldman

Article

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.

Aidixi Combination Therapy Improves Survival in Urothelial Carcinoma

May 14th 2025, 3:00pm

By Spencer Feldman

Article

Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.

Bone Metastasis Count May Guide Erleada Treatment in Prostate Cancer

May 14th 2025, 1:00pm

By Spencer Feldman

Article

The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases.

My Rare Cancer Gave Me Permission to Live

May 13th 2025, 9:00pm

By Linda Windham

Article

After walking alone in Chicago’s Cancer Survivor’s Walk, I found strength, healing and a renewed commitment to live fully and authentically — starting now.

Why Relationships are Key When Caring For Patients With MPNs

May 13th 2025, 8:00pm

By Kathryn Johnson, DNP

Video

Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.

Understanding the Unique Task of Treating Older Patients With Breast Cancer

May 13th 2025, 7:00pm

By Ryan Scott

Article

Dr. Hyman B. Muss discusses the unique challenges that older patients with breast cancer face during and after treatment for their disease.

I Found Strength After Surviving Multiple Myeloma and Through Recovery

May 13th 2025, 5:00pm

By Ronald Chin

Article

I share how I survived multiple myeloma, painful spine fractures and years of recovery to reclaim my independence and vitality.

Custom-Made Vaccine Combo Proves Effective in Bladder Cancer

May 13th 2025, 4:00pm

By Ryan Scott

Article

Treatment with a custom-made vaccine combination was found to be safe and feasible for patients with bladder cancer, eliciting a strong immune response.

Perjeta Regimen Improves Survival in HER2+ Early-Stage Breast Cancer

May 13th 2025, 3:00pm

By Spencer Feldman

Article

Treatment with Perjeta, Herceptin and chemotherapy post-surgery led to a significant overall survival benefit in HER2-positive early-stage breast cancer.

Cracked, Not Broken: Life After Breast Cancer

May 13th 2025, 1:00pm

By Tianja Grant

Article

Breast cancer cracked me open but didn’t break me — it gave me voice, purpose and courage to dream boldly, live fully and speak up for those who can’t.